Artelo Biosciences, Inc.
$1.42+4.41%(+$0.06)
TickerSpark Score
45/100
80
Valuation
20
Profitability
15
Growth
80
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTL research report →
52-Week Range0% of range
Low $1.25
Current $1.42
High $85.80
Companywww.artelobio.com
Artelo Biosciences, Inc. , a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.
- CEO
- Gregory D. Gorgas
- IPO
- 2019
- Employees
- 6
- HQ
- Solana Beach, CA, US
Price Chart
-75.52% · this period
Valuation
- Market Cap
- $3.10M
- P/E
- -0.08
- P/S
- 0.00
- P/B
- 0.16
- EV/EBITDA
- 0.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1602.50%
- ROIC
- -157.72%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,879,000 · -31.07%
- EPS
- $-5.47 · -438.09%
- Op Income
- $-11,404,000
- FCF YoY
- -2.04%
Performance & Tape
- 52W High
- $85.80
- 52W Low
- $1.25
- 50D MA
- $4.72
- 200D MA
- $9.22
- Beta
- 0.05
- Avg Volume
- 3.64M
Get TickerSpark's AI analysis on ARTL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 30, 26 | MATSUI CONNIE | other | 292 |
| Jan 30, 26 | Blayney Douglas | other | 292 |
| Jan 30, 26 | EMANUELE ROBERT MARTIN | other | 292 |
| Jan 30, 26 | Kelly Steven | other | 292 |
| Jan 30, 26 | FAVORITO TAMARA A | other | 292 |
| Jan 30, 26 | Reyes Gregory | other | 292 |
| Jan 29, 26 | Spring Mark Edward | other | 36,391 |
| Jan 29, 26 | Gorgas Gregory D. | other | 154,713 |
| Nov 1, 25 | Spring Mark Edward | other | 2,500 |
| Oct 28, 25 | MATSUI CONNIE | other | 70,376 |
Our ARTL Coverage
We haven't published any research on ARTL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARTL Report →Similar Companies
GTBP-2.49%
GT Biopharma, Inc.
$0.42
PTIX+0.00%
Protagenic Therapeutics, Inc.
$0.65
CARM+0.00%
Carisma Therapeutics, Inc.
$0.00
SLRX+29.23%
Salarius Pharmaceuticals, Inc.
$0.84
PBM+2.56%
Psyence Biomedical Ltd.
$4.01
REVB+5.83%
Revelation Biosciences, Inc.
$1.09
LIPO-17.56%
Lipella Pharmaceuticals Inc.
$0.14
SPRC-9.89%
SciSparc Ltd.
$4.10